VEGFA and cancer: The combination of the vascular endothelial growth factor (VEGF) inhibitor bevacizumab with the EGFR inhibitor erlotinib impairs glucose uptake by cancer cells, and it has accordingly been shown to be particularly effective in HLRCC compared with tumors that are less dependent on aerobic glycolysis [8,10].